As the treatment landscape continues to evolve, the expert faculty discuss how real-world considerations, including treatment access, insurance coverage, and patient costs, can significantly influence therapeutic decisions, sometimes as much as the clinical evidence itself.
As treatment options continue to expand, the expert faculty discuss where current evidence remains limited and identify key areas for future research that may further refine treatment selection and disease management.
CVAC and FANS reflect different surgical philosophies—dusting vs fragmentation—with distinct ergonomic trade-offs and shared intrarenal pressure risks that urologists must actively monitor, according to Krambeck.
Amar U. Kishan, MD, explains how to translate the ArteraAI result into a meaningful patient conversation, reflects on what the cost-effectiveness data mean for the future of AI-guided precision oncology, and closes with a single takeaway for community urologists.
Sender Herschorn, BSc, MDCM, FRCSC, discusses a subgroup analysis of the COURAGE trial showing that vibegron provided comparable efficacy and favorable safety in men aged 75 years and older with persistent OAB symptoms receiving pharmacotherapy for BPH.
New perioperative bladder cancer options reshape referrals and biomarker-driven planning, helping more patients get safer, personalized care.
Experts debate bladder MRI limits after TUR/chemo and how ctDNA/utDNA may refine staging and bladder-sparing decisions in muscle-invasive disease.
Urocross produced deepening IPSS improvement through 24 months post-retrieval, with Kevin T. McVary, MD, FACS, attributing a post-removal symptomatic boost to completed prostatic remodeling and full preservation of future treatment options.
Kristen Scarpato, MD, discusses 2026 AUA/SUO Advanced Prostate Cancer Guideline amendment recommendations on the use of PSMA-PET imaging for staging and treatment selection.
Results from a cross-sectional study suggest that unmet social needs are associated with kidney stone disease and worse stone-specific quality of life.
This episode, titled “Emerging Treatment Strategies in mCSPC,” features panelists discussing the rapidly evolving treatment landscape in metastatic castration-sensitive prostate cancer (mCSPC) and the growing number of therapeutic approaches being incorporated alongside androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs).
In “Risk Stratification and Treatment Intensification Strategies in mCSPC,” our panel explores how clinicians use clinical, molecular, and genomic risk factors to personalize treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how disease volume, timing of metastasis, tumor burden, PSA kinetics, and patient comorbidities influence risk stratification and guide the selection of doublet, triplet, and metastasis-directed treatment approaches.
Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without pre-biopsy mpMRI.
"This is really going to make access to care a lot better, and workflow is going to be a lot easier," says Ben H. Chew, MD, MSc, FRCSC.
In the final episode, “Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer,” the panelists explored the evolving role of treatment intensification strategies for patients with metastatic castration-sensitive prostate cancer (mCSPC). Using the case of a 63-year-old man with de novo high-volume metastatic disease, the expert faculty discussed how disease burden, patient fitness, comorbidities, and individual treatment goals influence decisions regarding doublet versus triplet therapy.
In this episode of The UroOnc Minute, host Adam Weiner, MD, is joined by David Canes, MD, for a thoughtful discussion on practical strategies to improve efficiency, reduce physician burnout, and preserve meaningful patient-centered care in urologic oncology.
Amar U. Kishan, MD, translates cost-effectiveness findings on the ArteraAI test into practical guidance for clinicians, payers, and health systems.
Enucleation is appropriate for the vast majority of patients with BPH, but certain patient profiles—including prior radiation, significant neurologic conditions, morbid obesity, and dementia—warrant caution or referral to specialists, whereas the most consistent technical failure among surgeons past their learning curve is inadequate apical tissue removal driven by discomfort with sphincter proximity, according to Amy E. Krambeck, MD.
Gopa Iyer, MD, reviews early NEXUS-01 data evaluating the investigational anti–Nectin-4 ADC LY4052031, highlighting the importance of CYP2D6-guided dosing to optimize safety.
Experts debate bladder MRI limits after TUR/chemo and weigh ctDNA/utDNA promise, yet accuracy gaps keep bladder-sparing decisions cautious.
ctDNA and urine DNA reshape bladder cancer care, guiding surgery timing and adjuvant therapy—yet key questions await clearer trials.
The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.
Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).
Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.
Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.
In “Managing High-Risk Biochemical Recurrence in Advanced Prostate Cancer,” our panel explores the evolving treatment landscape for patients experiencing biochemical recurrence following definitive therapy. Through the case of a 75-year-old man with a rising PSA after radical prostatectomy, a rapid PSA doubling time, and multiple cardiovascular and metabolic comorbidities, the expert faculty discuss how risk stratification and patient-specific factors influence treatment selection.
Kevin Koo, MD, MPH, highlights findings from a study evaluating automated kidney stone detection and measurement on CT.
In this video, Isaac Y. Kim, MD, PhD, MBA, discusses why immunotherapy may ultimately represent the next major advance in prostate cancer treatment.
Amar U. Kishan, MD, walks through the design and results of the Markov model-based cost-effectiveness analysis, explaining what it means for the ArteraAI-guided strategy to dominate both comparators and why that finding held up across a wide range of sensitivity analyses.
